Browsing Tag
BioIQ
15 posts
BioIQ Facilitating COVID-19 Testing for Tokyo Olympics
BioIQ, an analytics-driven population health and testing platform company for top U.S. employers, health plans, and government agencies,…
BioIQ Announced as 2021 Georgia Fast 40 Program Honoree by ACG Atlanta
BioIQ, an analytics-driven population health and testing platform company for top employers, health plans, and government agencies, was recently…
BioIQ and MLU Services Inc. Partner to Bring Mobile COVID-19 Vaccinations to Rural America
BioIQ, an analytics-driven population health and testing platform company for top employers, health plans, and government agencies, announces…
BioIQ Announces First End-to-End COVID-19 Mitigation Solution
BioIQ, an analytics-driven population health and testing platform company, introduces a first of its kind, end-to-end COVID-19 mitigation…
BioIQ Launches New Telehealth Solution for Diagnostic Testing and Population Health
BioIQ, an analytics-driven population health and testing platform company for top employers and health plans, announces the launch…
EY Announces Justin Bellante of BioIQ as an Entrepreneur of the Year® 2020 Southeast Award Finalist
Ernst & Young LLP (EY US) today announced that Justin Bellante of BioIQ was named an Entrepreneur Of The Year(®) 2020 Southeast Award finalist. Now in its 34th year, the Entrepreneur Of The Year program honors entrepreneurial business leaders whose ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses that transform our world. Bellante was selected as one of 30 finalists from a competitive pool of nominations by a panel of independent judges.
BioIQ Expands Return-to-Office Support Ecosystem to Help Employers Navigate COVID-19 Testing, Legal, and Workspace Considerations
BioIQ, a healthcare engagement and clinical adherence technology platform company, has partnered with Cresa and Ogletree Deakins to help employers navigate the many practical and legal issues to consider when crafting a workplace COVID-19 testing and return-to-work strategy. The BioIQ return-to-work ecosystem is designed to move employers up the learning curve quickly and expedite efforts to reopen the US economy.
BioIQ Launches Telehealth Enabled At-Home Saliva Test Kit for COVID-19 with P23 Labs
BioIQ, a healthcare engagement and clinical adherence technology platform company, announces the availability of an at-home RT-PCR COVID-19 testing solution with fully integrated telehealth support. The test is being offered in partnership with P23 Labs, one of the first laboratories to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for home saliva collection in conjunction with telehealth oversight. The partnership enables BioIQ to connect employees, health plan members, and individuals with COVID-19 diagnostic testing under the virtual supervision of a clinician.
BioIQ and Matrix Medical Network Unveil Back-to-Work COVID-19 Testing Program for US Employers
BioIQ, a healthcare engagement and clinical adherence technology platform company, and Matrix Medical Network, a clinical leader in supporting the needs of at-risk populations, announce the availability of a COVID-19 testing, testing protocol, assessment and monitoring program for US employers as the country lays out plans to bring employees back to work. With clinical oversight provided by Matrix's national array of locally based providers paired with BioIQ's comprehensive technology and testing platform, the two companies provide a robust solution that is designed to protect workers as the US readies for its first steps in re-opening the country.
BioIQ Adds Antibody Testing to its COVID-19 Testing Platform
BioIQ, a healthcare engagement and clinical adherence technology platform company, announces the addition of antibody testing to the company's innovative COVID-19 population health solutions, including saliva RT-PCR diagnostic testing, for health plans, employers and government agencies. The recently added enzyme-linked immunosorbent assay (ELISA) test is the preferred standard in antibody testing and uses a blood or serum sample to determine whether an immunoglobulin (IgG/IgM) antibody is present in the test subject.